Skip To Main Content
Barnaby Flower on Muck Rack

Barnaby Flower

As seen in: Thorax, CNA (Channel NewsAsia), The Lancet, East Asia Forum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barnaby

Contact Barnaby, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial

|
By Graham Cooke Verified, Viet Nam, Barnaby Flower
| The Lancet Verified
Introduction The development of direct-acting antivirals for hepatitis C virus (HCV) infection has transformed individual treatment and underpins ambitious WHO targets for global elimination of viral hepatitis as a public health threat by 2030.1 Of three WHO-recommended pan-genotypic first-line treatment options, two are preferred by lower-income and lower-middle-income countries and are available from generic manufacturers: sofosbuvir–daclatasvir and sofosbuvir–velpatasvir.2 No randomised...
Open in Who Shared Issue with article?

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial

|
By Graham Cooke Verified, Viet Nam, Barnaby Flower, Leanne McCabe
| The Lancet Verified
Introduction The development of direct-acting antivirals for hepatitis C virus (HCV) infection has transformed individual treatment and underpins ambitious WHO targets for global elimination of viral hepatitis as a public health threat by 2030.1 Of three WHO-recommended pan-genotypic first-line treatment options, two are preferred by lower-income and lower-middle-income countries and are available from generic manufacturers: sofosbuvir–daclatasvir and sofosbuvir–velpatasvir.2 No randomised...
Open in Who Shared Issue with article?

Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update

|
By Graham Cooke Verified, Barnaby Flower, Evan B. Cunningham, UNSW Sydney
| The Lancet Verified
1. Cooke GS Andrieux-Meyer I Applegate TL et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019; 4: 135-184 2. Ward JW Wiktor SZ Cooke GS Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020; 5: 8-10 3.
Open in Who Shared Issue with article?
See all 63 articles